TRPA1 deficiency is protective in cuprizone-induced demyelination-A new target against oligodendrocyte apoptosis
- PMID: 27568827
- DOI: 10.1002/glia.23051
TRPA1 deficiency is protective in cuprizone-induced demyelination-A new target against oligodendrocyte apoptosis
Abstract
Multiple sclerosis is a chronic inflammatory, demyelinating degenerative disease of the central nervous system. Current treatments target pathological immune responses to counteract the inflammatory processes. However, these drugs do not restrain the long-term progression of clinical disability. For this reason, new therapeutic approaches and identification of novel target molecules are needed to prevent demyelination or promote repair mechanisms. Transient Receptor Potential Ankyrin 1 (TRPA1) is a nonselective cation channel with relatively high Ca2+ permeability. Its pathophysiological role in central nervous system disorders has not been elucidated yet. In the present study, we aimed to assess the distribution of TRPA1 in the mouse brain and reveal its regulatory role in the cuprizone-induced demyelination. This toxin-induced model, characterized by oligodendrocyte apoptosis and subsequent primary demyelination, allows us to investigate the nonimmune aspects of multiple sclerosis. We found that TRPA1 is expressed on astrocytes in the mouse central nervous system. Interestingly, TRPA1 deficiency significantly attenuated cuprizone-induced demyelination by reducing the apoptosis of mature oligodendrocytes. Our data suggest that TRPA1 regulates mitogen-activated protein kinase pathways, as well as transcription factor c-Jun and a proapoptotic Bcl-2 family member (Bak) expression resulting in enhanced oligodendrocyte apoptosis. In conclusion, we propose that TRPA1 receptors enhancing the intracellular Ca2+ concentration modulate astrocyte functions, and influence the pro or anti-apoptotic pathways in oligodendrocytes. Inhibition of TRPA1 receptors might successfully diminish the degenerative pathology in multiple sclerosis and could be a promising therapeutic target to limit central nervous system damage in demyelinating diseases. GLIA 2016;64:2166-2180.
Keywords: MAPK; TRPA1; cuprizone; demyelination; oligodendrocyte.
© 2016 Wiley Periodicals, Inc.
Similar articles
-
Behavioural alterations and morphological changes are attenuated by the lack of TRPA1 receptors in the cuprizone-induced demyelination model in mice.J Neuroimmunol. 2018 Jul 15;320:1-10. doi: 10.1016/j.jneuroim.2018.03.020. Epub 2018 Apr 6. J Neuroimmunol. 2018. PMID: 29759134
-
Cuprizone-induced graded oligodendrocyte vulnerability is regulated by the transcription factor DNA damage-inducible transcript 3.Glia. 2019 Feb;67(2):263-276. doi: 10.1002/glia.23538. Epub 2018 Dec 3. Glia. 2019. PMID: 30511355
-
Investigation of Cuprizone-Induced Demyelination in mGFAP-Driven Conditional Transient Receptor Potential Ankyrin 1 (TRPA1) Receptor Knockout Mice.Cells. 2019 Dec 28;9(1):81. doi: 10.3390/cells9010081. Cells. 2019. PMID: 31905673 Free PMC article.
-
Five Decades of Cuprizone, an Updated Model to Replicate Demyelinating Diseases.Curr Neuropharmacol. 2019;17(2):129-141. doi: 10.2174/1570159X15666170717120343. Curr Neuropharmacol. 2019. PMID: 28714395 Free PMC article. Review.
-
Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination.Mol Neurodegener. 2022 May 7;17(1):34. doi: 10.1186/s13024-022-00538-8. Mol Neurodegener. 2022. PMID: 35526004 Free PMC article. Review.
Cited by
-
Nociception in a Progressive Multiple Sclerosis Model in Mice Is Dependent on Spinal TRPA1 Channel Activation.Mol Neurobiol. 2020 May;57(5):2420-2435. doi: 10.1007/s12035-020-01891-9. Epub 2020 Feb 24. Mol Neurobiol. 2020. PMID: 32095993
-
Neuroprotective effects of rutin against cuprizone-induced multiple sclerosis in mice.Inflammopharmacology. 2024 Apr;32(2):1295-1315. doi: 10.1007/s10787-024-01442-x. Epub 2024 Mar 21. Inflammopharmacology. 2024. PMID: 38512652 Free PMC article.
-
Computational Drug Repurposing Algorithm Targeting TRPA1 Calcium Channel as a Potential Therapeutic Solution for Multiple Sclerosis.Pharmaceutics. 2019 Sep 2;11(9):446. doi: 10.3390/pharmaceutics11090446. Pharmaceutics. 2019. PMID: 31480671 Free PMC article.
-
Inhibition of TRPA1 Ameliorates Periodontitis by Reducing Periodontal Ligament Cell Oxidative Stress and Apoptosis via PERK/eIF2α/ATF-4/CHOP Signal Pathway.Oxid Med Cell Longev. 2022 Jun 10;2022:4107915. doi: 10.1155/2022/4107915. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 35720191 Free PMC article.
-
Transient receptor potential Ankyrin-1 (TRPA1) agonists suppress myelination and induce demyelination in organotypic cortical slices.Glia. 2023 Jun;71(6):1402-1413. doi: 10.1002/glia.24347. Epub 2023 Feb 10. Glia. 2023. PMID: 36762504 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous